A Review of the Research Progress and Application of Skin Care Ointments in Chronic Eczema Treatment ...

Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...

AMGN made an upfront payment of $400 million to Kyowa. Apart from eczema, the companies are also developing the drug for prurigo nodularis (phase III) and asthma (phase II). Each was handpicked by ...

While the IGNITE study evaluated rocatinlimab as monotherapy for 24 weeks, the SHUTTLE study evaluated the drug in combination with topical corticosteroids (TCS) and/or topical calcineurin ...

Topical steroid withdrawal diagnostic criteria defined by NIH researchers: Bethesda, Maryland Monday, March 17, 2025, 15:00 Hrs [IST] Researchers at the National Institutes of Hea ...

NIH researchers define diagnostic criteria for topical steroid withdrawal (TSW), distinguishing it from eczema.

Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis ...